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ABSTRACT 
 We reported the stepwise formation of biocompatible poly(L-lysine)/poly(L-
glutamic acid) (PLL/PGA) multilayer films on mesoporous silica (MS) spheres via 
layer-by-layer (LbL) self-assembly technique. In-situ QCM revealed the nonlinear 
(exponential) growth of PLL/PGA multilayer films at both pH 5.5 and pH 7.0 
conditions. ξ-potential measurements of the multilayer coated particles indicated that 
the multilayer surface is being charge-overcompensated in each adsorption step, 
thereby facilitating adsorption of the next oppositely charged polypeptide onto the MS 
spheres. Hollow polypeptide capsules could be obtained by subsequently removing 
silica cores. By using enzyme-preloaded MS spheres as capsule templates, a general 
approach was developed for encapsulating enzymes in biocompatible microcapsules 
with high loading and retained bioactivity. The loading amount for several enzymes 
with different sizes and their bioactivity after encapsulation were also reported. 
Keywords: Biocompatible hollow capsules; Mesoporous silica; Layer-by-layer 
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1. Introduction 
In the last decade, the layer-by-layer (LbL) self-assembly method, which is 
based on the stepwise electrostatic assembly of oppositely charged species [1,2], has 
emerged as a promising and versatile approach to the fabrication of functional 
molecular assemblies with well-defined architectures. A great advantage offered by 
the LbL technique is its ability to coat substrates of various shapes and sizes with 
uniform layers of varying composition (e.g., polymers, biological macromolecules, 
dyes and nanoparticles) and the achievement of controllable thickness at a molecular 
scale. The geometry of the substrates is not necessarily planar but can be curved or 
spherical. The extension of the LbL method to colloidal particles and the subsequent 
removal of the template core has led to a viable alternative for preparing hollow 
capsules with controlled composition, wall thickness and size [3-5], which are of great 
usefulness in the encapsulation of functional materials [5,6]. More recently, the 
method has also been extended to the coating of multilayer films onto porous particles 
[7-10]. For example, by employing interlayer cross-linking, multilayer films of 
polyelectrolytes (PEs) were successfully deposited into the pores of mesoporous silica 
spheres, which provides an effective way to prepare nanoporous solid PE spheres with 
controlled diameter and excellent capacity for immobilizing biomolecules [7]. 
Sukhorukov and co-workers demonstrated that LbL coating of porous inorganic 
microparticles of calcium carbonate followed by core removal resulted in the matrix 
polyelectrolyte microcapsules which also have good capability of loading 
macromolecules [9,10]. 
Within the past few years, there has been increasing interests in the preparation 
and biomedical application
  of biocompatible multilayer films that constructed by 
natural polyelectrolytes (e.g. hyaluronan, alginate, chitosan, collagen) and ACCEPTED MANUSCRIPT
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polypeptides (e.g., PLL, PGA) [11-14]. For example, multilayer films of 
dextran/chitosan have the properties of pro- or anti-coagulation depending on the 
outmost layer of the film [11]. In a recent study, Picart et al reported that the cell 
adhesive behaviour could be controlled by the structure and architecture of PLL/PGA 
multilayer films, which could be tuned by varying the pH values during film 
preparation [13]. However, most of the previous studies on biocompatible multilayer 
films have been focussed on films deposited on flat substrates. It is of great interest to 
coat these films onto colloidal particles, as it will not only provide further insight into 
the deposition and layer properties of these films, but also afford a new class of 
colloidal particles and hollow capsules with biocompatible surfaces. In the present 
work, we take polypeptides PLL/PGA as example to examine the progressive coating 
of multilayer films onto mesoporous silica (MS) spheres via the LbL self-assembly 
technique. Because most of the biocompatible polymers are weak polyelectrolytes 
(polymers with degrees of dissociation that depend strongly on pH) and particles 
coated with weak polyelectrolytes easily lose their colloidal stability during the 
coating process [15], buffer solutions are used to control the pH condition throughout 
the multilayer film coating process. We also demonstrate the preparation of hollow 
polypeptide capsules by subsequently removing the silica cores. Based on these 
studies, a general approach is developed for encapsulating biomolecules into hollow 
capsules with high loading and retained bioactivity by using enzyme pre-loaded MS 
spheres as capsule templates. 
 
2. Experimental 
2.1. Materials  
Poly(L-lysine) hydrobromide (PLL, MW 30,000 – 70,000 g mol
-1), poly(L-
glutamic acid) (PGA, MW 50,000–100,000 g mol
-1), urease (U4002), catalase (C-100), ACCEPTED MANUSCRIPT
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peroxidase (POD, P8250), Poly(ethyleneimine) (PEI, Mw 25 000), 2-(N-morpholino) 
ethanesulfonic acid (MES), fluorescein isothiocyanate (FITC), hydrogen peroxide 
(H2O2), hydrofluoric acid (HF), ammonium fluoride (NH4F), urea, CaCl2, sodium 
metasilicate (Na2SiO3), tetraethyl orthosilicate (TEOS, 98%), and dimethylsulfoxide 
(DMSO) were obtained from Sigma-Aldrich and used as received. Lysozyme was 
from Fluka BioChemika. Mesoporous silica (MS) spheres of 2-4 μm diameter, were 
synthesised according to a literature method [16]. Phosphate buffer (PB) solutions of 
pH 7 and 8 were prepared using 0.05 M Na2HPO4 and by adjusting the pH with 0.1 M 
HCl. The solution used for dissolving the silica core was a mixture of 2 M HF and 8 
M NH4F at pH ~ 5. The water used in all experiments was prepared in a Millipore 
Milli-Q purification system and had a resistivity higher than 18 MΩ cm. 
2.2. Preparation of FITC-labelled polypeptide and enzymes 
FITC-labelled PLL or enzyme (e.g., catalase, lysozyme) was prepared by adding 
0.3 mL of 1 mg mL
-1 FITC/DMSO solution to 4.0 mL of a 1.0 mg mL
-1 PLL or 
enzyme solution in pH 8.0 PB and allowing it to stand at 20
oC for 45 min. The 
suspension was then dialysed against PB buffer for 72 h, changing the solution every 
24 h.  
2.3. Quartz crystal microbalance (QCM) measurements 
QCM measurements were made by using a Q-sense D300 device equipped with a 
flow cell (Q-Sense AB, Västra Frölundra, Sweden). The temperature of the 
measurement chamber was kept at 20.5
oC during the experiments. A gold-coated 5 
MHz AT-cut quartz crystal was excited at its third overtone (~15 MHz) and the 
change in the resonance frequency (ΔF) was recorded. The frequency values obtained 
were divided by 3 for direct comparison with the base frequency data obtained at 5 ACCEPTED MANUSCRIPT
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MHz. The Sauerbrey equation was used to calculate the mass of the adsorbed layers 
from ΔF values [17].
 For the set-up employed, a correlation factor of C = 17.7 ng Hz
-1 
cm
-2 applies. The QCM electrodes were cleaned by piranha treatment (one part 30% 
H2O2 to three parts 98% H2SO4). (Caution: Piranha solution is a strong oxidizing 
agent which causes severe burns in contact with skin and reacts violently with 
organic materials.) A PEI layer was then deposited, followed by thorough rinsing 
with water. Alternating layers of PGA/PLL at different pH values were then adsorbed 
onto the QCM electrodes with interlayer buffer washing. 
2.4. PLL/PGA microcapsule formation and enzyme encapsulation 
Approximately 5 mg of bare or enzyme-loaded MS particles (see Table 1 for 
detailed adsorption conditions used for different enzymes) were added to 1 mg mL
-1 
PLL solution (prepared in 0.05 M MES buffer at pH 5.5 without salt, 5°C) for 10 min, 
with occasional shaking. Excess polyelectrolyte was removed by three centrifugation 
(500g for 5 min)/redispersion cycles using pH 5.5 MES buffer solution. The PGA 
layer was adsorbed using the same procedure. This process was repeated until three 
(PLL/PGA) bilayers were deposited. Hollow or enzyme-encapsulated PLL/PGA 
microcapsules were obtained by dissolving the MS particle templates in HF/NH4F 
solution for 5 min, followed by three centrifugation (1500 g for 5 min)/MES buffer 
washing cycles. The amount of enzyme adsorbed on MS particles or encapsulated in 
capsules was determined by using a Standard Micro BCA
TM Protein Assay kit (Pierce, 
Product No. 23209).  
2.5. Characterization 
ζ-potentials were measured on a Zetasizer 2000 (Malvern) instrument. 
Transmission electron microscopy (TEM) samples were prepared by placing a drop of ACCEPTED MANUSCRIPT
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a diluted suspension (dispersed in water) onto a TEM grid and were measured on a 
Philips CM 120 microscope operated at 120 kV. Confocal laser scanning microscopy 
(CLSM) images were taken with an Olympus confocal system equipped with a 60x 
oil immersion objective.  
3. Results and discussion 
3.1. PLL/PGA multilayer film assembly 
In order to gain a better understanding of the multilayer deposition process, in-situ 
QCM experiments were first conducted to examine the formation of PLL/PGA films 
on planar supports. Figure 1 shows the frequency change (ΔF) trend for the formation 
of multilayer films in pH 7.0 (Figure 1a) and pH 5.5 (Figure 1b) buffer solutions. The 
electrodes were first primed with a layer of PEI, and alternating layers of PGA/PLL 
were then deposited with intermediate buffer washing steps. The frequency decrease 
corresponds to an increase in adsorbed mass on the electrode. A systematic decrease 
in the QCM frequency is observed, indicating the successful formation of a PGA/PLL 
multilayer film at both pH conditions. However, unlike the normal polyelectrolyte 
multilayer films with linear thickness and mass growth, PLL/PGA multilayer films 
exhibit a nonlinear mass growth, i.e. the material adsorbed on the electrode increases 
more than linearly with the number of deposited layers. This nonlinear or exponential 
growth of the film was also observed previously in the formation of PLL/PGA films 
on other substrates [13,18,19] and in films comprising PLL or PGA, for example, 
PLL/hyaluronic acid [20]
 and PGA/poly(allylamine hydrochloride) [21]
 multilayer 
films. Previous studies on polyelectrolyte LbL multilayer films have demonstrated 
that the growth of the multilayer film is entropy driven and an endothermic 
complexation process of PLL/PGA corresponds to the exponential growth of the film 
[22]. The high mobility of the polymers that comprise the film, i.e., the diffusion in ACCEPTED MANUSCRIPT
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and out of PGA and/or PLL of the whole film during each deposition step, is also 
believed to contribute to the exponential growth [23,24]. The larger increase of ΔF 
during PLL injection indicates that PGA is the main diffusing species. As the 
diffusion of PGA (PI ~3.5) is more favourable at pH 5.5 than pH 7 due to lower 
charge density, the nonlinear growth of the film becomes more pronounced at pH 5.5.  
3.2. PLL/PGA multilayer film assembly on MS spheres  
The PLL/PGA layers were then deposited onto MS spheres by using the same 
conditions as those employed for the QCM experiments. The stepwise growth of the 
multilayer shells onto MS spheres at pH 5.5 was monitored by following the ζ-
potential changes for the particles after each deposition step (Figure 2). At pH 5.5, 
PLL is positively charged (PI ~9) while PGA is negatively charged (PI ~3.5). The 
original MS spheres have a ζ-potential of ca. −40 mV. The ζ-potential alternates after 
each new PLL and PGA adsorption and becomes positive (~+40 mV) or negative 
(~−35 mV) respectively, which indicated that the multilayer surface is being charge-
overcompensated in each adsorption step, thereby facilitating adsorption of the next 
oppositely charged polypeptide to form the multilayer film onto MS particles. 
The build-up of the PLL/PGA multilayer on MS particles is then characterized by 
TEM. Figure 3a shows the TEM image of bare MS spheres which have a particle size 
ranging from 2–4 µm. At higher magnification (Figure 3a, inset), the disordered 
porous structure becomes apparent. Figure 3b shows the low and high (inset) 
magnification TEM image of MS particles after three-bilayer PLL/PGA coating. 
Compared with uncoated MS particles (Figure 3a), the polypeptide coated particles 
show a higher electron density on the shell, indicating that the polypeptide coating lies 
on the particle surface as well as to some extent in the mesopores due to the 
permeation of polypeptide chains into the mesopores [7]. The formation of the ACCEPTED MANUSCRIPT
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PLL/PGA multilayer shell is further confirmed by dissolving the silica template cores 
in HF solution (2 M HF/8 M NH4F at pH ~5), as shown in Figure 3c. The 
(PLL/PGA)3 capsules totally collapse upon drying due to the removal of silica core. 
Folds and creases are clearly seen on their surface. The removal of the template was 
confirmed by energy-dispersive X-ray analysis, which showed about 5% of atomic 
silicon (excluding C and H) present after exposure to HF/NH4F for 5 min. Further 
exposure to HF/NH4F did not reduce the silica content.  
The formation of (PLL/PGA)3 capsules can be clearly seen under confocal laser 
scanning microscopy (CLSM) when using FITC-labeled PLL in the PLL/PGA 
multilayer coating. Figure 4a shows CLSM image of (FITC-PLL/PGA)3 coated MS 
spheres after dissolution of silica and resuspension in pH 5.5 buffer solution. The 
bright rings in solution indicate the successful formation of PLL/PGA multilayer 
shells. The approximately 2-4 μm capsule size suggests that the resultant hollow 
capsules keep the shape and size of the original MS sphere templates. The fact that no 
shrinkage or breakage of the capsules was observed indicates that the three-bilayer 
PLL/PGA coating is rather stable during the silica core dissolution process.  
3.3. Enzyme encapsulation in PLL/PGA microcapsules 
We have shown the successful formation of PLL/PGA multilayer films on MS 
spheres and the resultant PLL/PGA capsules by removing the silica templates. If we 
coat the multilayer film on enzyme preloaded MS spheres, we should be able to 
directly encapsulate enzymes into PLL/PGA microcapsules. The MS spheres used 
have a bimodal pore structure (small pores of 2-3 nm and large pores of 10-40 nm), a 
surface area of 630 m
2 g
-1 and a pore volume of 1.72 mL g
-1 [25-28]. The ability of 
the MS spheres for immobilizing enzymes with different sizes is shown in Table 1. It 
is observed that enzymes with small size normally adsorb rapidly into the MS ACCEPTED MANUSCRIPT
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particles with high loading. For example, 1 g MS spheres can load 412 mg lysozyme 
(ca. 4 nm), which is about 5.5 and 6 times of the loading amounts for large enzymes 
catalase (ca. 10 nm) and urease (ca. 13 nm). In addition, since electrostatic interaction 
is a main driving force for adsorbing enzymes into MS spheres, enzymes with 
opposite charge to the MS material (PI ~2) [29] is beneficial for obtaining high 
loading.  
The enzyme-loaded MS spheres are then coated with PLL/PGA multilayer films 
in pH 5.5 MES buffer. The pH 5.5 condition was chosen to be similar to the silica 
dissolution solution (pH 5) in order to minimize the structural changes of the 
polypeptide multilayer in HF solution, which is found to be important in reducing the 
possible enzyme loss during silica dissolution process [35]. When the enzyme-loaded 
MS spheres were dispersed in PLL solutions, it was observed that some enzyme 
molecules desorb from the MS spheres. The desorbed enzyme amount varies greatly 
for different enzymes which is mainly dependent on how strong enzyme molecules 
adsorb on silica. If the interaction between enzyme and MS is weaker than the 
interaction between enzyme and PLL, the enzyme molecules tend to desorb from the 
MS spheres resulting in a reduced loading amount in capsule. For example, the 
loading amount of POD in 1g MS spheres is 150 mg which is double the loading 
amount of catalase. However, when exposed to PLL, due to the very weak interaction 
between POD and silica, nearly 90% of the POD molecules desorb from the MS 
spheres while very few catalase desorption is observed, which resulted in the final 
loading amount of POD in the capsules being much less than that of catalase (Table 1). 
It should be noted that this is the main step in which the loaded enzyme is lost. After 
forming the PLL layer, the PLL coating network blocks the mesopores and provides ACCEPTED MANUSCRIPT
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an effective protective barrier for the loaded enzyme. As a result, very little enzyme 
leakage is detected during the subsequent multilayer coating process.  
Following removal of the MS template with HF/NH4F, (PLL/PGA)3 
microcapsules with encapsulated enzyme were obtained. The immobilization and 
distribution of enzyme in the capsules were examined by CLSM. Figure 4b shows the 
CLSM image of FITC-lysozyme encapsulated (PLL/PGA)3 capsules. It can be seen 
that the whole interior of the enzyme loaded capsules displays homogeneous 
fluorescence, indicating that relatively high amounts of enzyme molecules are 
successfully encapsulated in the capsules. Controlled experiments of enzyme-loaded 
(FITC-PLL/PGA)3  microcapsules shows that the fluorescence intensity from PLL 
only arises from the capsule shell and not the interior. The results suggest that most of 
the enzyme molecules are freely contained within the capsule, i.e., not forming a 
complex with PLL, making it very attractive for release applications. The final 
enzyme amount encapsulated in the (PLL/PGA)3 microcapsules, as shown in Table 1, 
varies greatly for different enzymes (see discussions above). The high enzyme loading, 
particularly for large enzymes (>10 nm) that are difficult to load into pre-formed 
hollow capsules is noteworthy.  
It is important that the encapsulated enzymes can survive the HF treatment and 
keep their biological activity. We thus take urease as an example to measure the 
activity after encapsulation. Urease is an enzyme that catalyzes the hydrolysis of urea. 
The activity of urease can be quantitatively examined by a pH-sensitive dye (phenol 
red) in a mixed buffer solution containing urea, according to a standard procedure 
[30]. The activity of urease in the PLL/PGA microcapsules is measured to be ~49% of 
its original value in solution. This decrease in bioactivity is mainly due to the 
diffusion limitations in the enzymatic reaction, which typically happens when ACCEPTED MANUSCRIPT
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enzymes are in an immobilized state [26,28,31]. However, compared with some 
recent reports on urease immobilization, for example, urease immobilized in 
halloysite nanotube (~17%) [32] and urease post-infiltrated in poly(allylamine 
hydrochloride)/poly(styrene sulfonate) capsules (~13%) [33], this activity value is still 
much higher, which we attribute to that urease is largely in a free state in the 
microcapsules. The results also suggest that the HF buffer used for silica dissolution 
does not significantly decrease the enzymatic activity. In addition, it should be 
mentioned that although the enzyme activity decreases after encapsulation, the 
encapsulated enzyme showed an enhanced lifetime and reaction stability than the free 
enzyme in solution. Our recent study also showed that the urease-loaded 
microcapsules could act as biomimetic reactors to precipitate calcium carbonate 
exclusively in the capsule interior [28].
 
4. Conclusions 
In summary, we have demonstrated the successful formation of biocompatible 
PLL/PGA multilayer films both on planar substrates and mesoporous silica spheres by 
means of in-situ QCM, ξ-potential, TEM and confocal microscopy characterization. 
The PLL/PGA multilayer films exhibit nonlinear growth at both pH 7.0 and 5.5 
conditions, which is due to the diffusion in and out of PGA and/or PLL of the whole 
film during each deposition step. By using enzyme-preloaded MS spheres as the 
capsule template and following silica dissolution, the current method provides an 
effective way to encapsulate various enzymes in biocompatible microcapsules with 
high loading and retained activity. Our recent study also showed that the encapsulated 
enzyme could be readily released by altering the polyelectrolyte shell permeation via 
changing solution pH or salt concentration
 [27]. Due to the immobilization capacity of 
mesoporous silica for various materials and the biocompatibility as well as the easy ACCEPTED MANUSCRIPT
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functionalization of the capsule shell, it is likely that this method can be extended to 
encapsulate many other materials and find wide application in various fields such as 
controlled cellular drug delivery. 
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Figure Captions 
 
Fig. 1. Real-time monitoring of the formation of PLL/PGA multilayer films on QCM 
electrodes in pH 7.0 PB (a) and pH 5.5 MES buffer solution (b). A PEI layer was 
deposited first, followed by alternating layers of PGA (1 mg mL
-1) and PLL (1 mg 
mL
-1) in buffer solutions. Intermediate buffer washing steps were used. 
Fig. 2. Variation in the ζ-potential for the deposition of PLL/PGA multilayer shells on 
MS spheres. The ζ-potential measurements were performed in Milli-Q water at pH 5.8. 
Layer number 0 corresponds to the bare MS spheres. Layer numbers 1, 3, 5 
correspond to PLL deposition, and layer numbers 2, 4, 6 correspond to PGA 
deposition.  
Fig. 3. TEM images of bare MS spheres (a), MS spheres after coating with 
(PLL/PGA)3 multilayer films (b) and the resultant (PLL/PGA)3 microcapsules after 
removing MS template. Inset scale bar 100 nm for (a), (b) and 1µm for (c). 
Fig. 4. CLSM images of (FITC-PLL/PGA)3 microcapsules (a) and FITC-lysozyme 
loaded (PLL/PGA)3  microcapsules (b) prepared by templating MS spheres.  
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Table 1. Enzyme properties and immobilized amounts in MS particles and PLL/PGA 
capsules. 
 
Enzyme 
Mw 
/ k Da  
Size 
/ 
nm 
pI Adsorption 
condition 
  
Enzyme 
adsorbed in MS 
particles 
mg/g 
a 
Enzyme loading in 
(PLL/PGA)3 
capsule 
 mg /mL
b 
 
Lysozyme 
 
14.6 
 
4 
 
11 
 
2 mg.mL
-1 pH 7.0  
PB overnight 
 
412 
 
 
185 
POD 44  4.8  8  1 mg.mL
-1 water 
overnight 
150 7 
Catalase 250  10.4  5.4 1  mg.mL
-1 pH 7.0  
PB 3 days 
75 38 
Urease 480  13  6  2  mg.mL
-1 pH 5.5 
MES 3 days 
67 25 
a  The enzyme amount (mg) adsorbed on per gram of MS particles at saturation 
adsorption.  
b The final enzyme concentration in the capsule was calculated assuming a density of 
MS spheres of 0.46 g cm
-3 and no change in size of capsules during core dissolution.  
  
 ACCEPTED MANUSCRIPT
ACCEPTED MANUSCRIPT
  1
Graphical Abstract 
 
  
 
Enzyme preloaded mesoporous silica (MS) particles were used as templates for the layer-by-
layer deposition of biocompatible polypeptide multilayer film to prepare microcapsules with high 
active enzyme loading upon subsequently MS template core dissolution.  
 
 
 
 
 
 